- Home
- NLOP vs KMDA Comparison
NLOP vs KMDA Comparison
Compare NLOP & KMDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NLOP
- KMDA
- Stock Information
- Founded
- NLOP 2022
- KMDA 1990
- Country
- NLOP United States
- KMDA Israel
- Employees
- NLOP N/A
- KMDA N/A
- Industry
- NLOP
- KMDA Biotechnology: Pharmaceutical Preparations
- Sector
- NLOP
- KMDA Health Care
- Exchange
- NLOP Nasdaq
- KMDA Nasdaq
- Market Cap
- NLOP 470.6M
- KMDA 442.1M
- IPO Year
- NLOP N/A
- KMDA N/A
- Fundamental
- Price
- NLOP $31.85
- KMDA $7.46
- Analyst Decision
- NLOP Strong Buy
- KMDA Strong Buy
- Analyst Count
- NLOP 1
- KMDA 2
- Target Price
- NLOP $46.00
- KMDA $14.50
- AVG Volume (30 Days)
- NLOP 145.9K
- KMDA 342.2K
- Earning Date
- NLOP 01-01-0001
- KMDA 03-05-2025
- Dividend Yield
- NLOP 1.07%
- KMDA N/A
- EPS Growth
- NLOP N/A
- KMDA 124.29
- EPS
- NLOP N/A
- KMDA 0.27
- Revenue
- NLOP $160,911,000.00
- KMDA $158,380,000.00
- Revenue This Year
- NLOP N/A
- KMDA $15.37
- Revenue Next Year
- NLOP N/A
- KMDA $8.58
- P/E Ratio
- NLOP N/A
- KMDA $28.13
- Revenue Growth
- NLOP N/A
- KMDA 4.52
- 52 Week Low
- NLOP $22.16
- KMDA $4.74
- 52 Week High
- NLOP $34.38
- KMDA $9.15
- Technical
- Relative Strength Index (RSI)
- NLOP 49.95
- KMDA 52.89
- Support Level
- NLOP $30.69
- KMDA $7.51
- Resistance Level
- NLOP $34.38
- KMDA $8.35
- Average True Range (ATR)
- NLOP 0.85
- KMDA 0.41
- MACD
- NLOP 0.06
- KMDA -0.02
- Stochastic Oscillator
- NLOP 31.46
- KMDA 33.20
About NLOP Net Lease Office Properties of Beneficial Interest
Net Lease Office Properties is a real estate investment trust. Through its subsidiaries it owns, operates, and finances office buildings. Its properties are primarily leased to corporate tenants on a single-tenant, net-lease basis. Its portfolio includes approximately 1.5 million square feet of Green-Certified Buildings, 4 LEED-Certified Buildings, and 1 BREEAM-Certified Building.
About KMDA Kamada Ltd.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, Proprietary Products segment and Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.